News & Events
-
June 28, 2021
REQUEST FOR PROPOSAL: OMOP CDM Mapping, Training, and Consulting
C-Path’s Data Collaboration Center’s Data Science Team is seeking proposals from U.S.-based vendors to provide expertise and on-demand services related to the Observational Health Data Sciences and Informatics (OHDSI) Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) for our rare disease data sharing platform, the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). We...... -
May 19, 2021
ERA4TB Update
NEWSLETTER: The ERA4TB (European Regimen Accelerator for Tuberculosis) project, a public-private initiative devoted to accelerating the development of new treatment regimens for tuberculosis, issued its first newsletter this month which includes updates on the project thus far. Read the full communication and subscribe, here: https://era4tb.org/newsletter.
-
April 22, 2021
Data Collaboration Center Request for Proposal
RFP: The RDCA Branding & Web Portal Data Collaboration Center’s (DCC’s) platform development team is seeking a proposal, including timelines and budget, to build a user portal for our rare disease data sharing platform – Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). RFP: RDCA Branding & Web Portal... -
February 17, 2021
C-Path’s Data Collaboration Center Seeks Proposals
The Critical Path Institute Data Collaboration Center is seeking proposals for the creation of non-identifiable, synthetic patient-level EHR datasets. The proposal submission deadline is February 26, 2021. Please send any questions you have about the RFP to Amanda J. Borens, MS, Executive Director of Data Science, aborens@c-path.org by February 19, 2021. Include “EHR RFP” in the subject line.
-
October 28, 2020
C-Path and EATRIS To Collaborate on RDCA-DAP
C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …